- TheStreet.com•7 days ago
Sangamo Therapeutics, Impax Laboratories and Portola Pharmaceutical are among the premarket movers in biotech.
- TheStreet.com•9 days ago
Impax Laboratories, Sangamo Therapeutics and Aralez Pharmaceuticals are among the premarket movers in biotech.
- PR Newswire•9 days agoSangamo Therapeutics Receives Orphan Drug Designation from the FDA for SB-318 Genome Editing Treatment for MPS I
RICHMOND, Calif., Jan. 11, 2017 /PRNewswire/ -- Sangamo Therapeutics, Inc. (SGMO), the leader in therapeutic genome editing, announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to SB-318, a genome editing product candidate for the treatment of Mucopolysaccharidosis Type I (MPS I), a rare lysosomal storage disorder. Orphan drug designations are granted to drugs and biologics intended to treat rare diseases. Using Sangamo's zinc finger nuclease (ZFN) genome editing technology, SB-318 is designed as a single treatment strategy intended to provide stable, continuous production of the IDUA enzyme for the lifetime of the patient.
SGMO: Summary for Sangamo Therapeutics, Inc. - Yahoo Finance
Sangamo Therapeutics, Inc. (SGMO)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
|Bid||3.25 x 100|
|Ask||4.10 x 500|
|Day's range||3.77 - 4.15|
|52-week range||2.65 - 7.60|
Trade prices are not sourced from all markets
|PE ratio (TTM)||-3.66|
|Dividend & yield||N/A (N/A)|
|1y target est||N/A|